{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2847","value":"6433"},{"groupId":"OG001","spread":"1671","value":"9117"},{"groupId":"OG002","spread":"163","value":"1125"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Number of tumor-responsive (interferon-gamma positive (IFNg+)) immune cells in blood post dosing","dispersionType":"Standard Error","groups":[{"description":"0.015 mg/kg/dose of ALT-801","id":"OG000","title":"ALT-801 0.015 mg/kg/Dose"},{"description":"0.040 mg/kg/dose of ALT-801","id":"OG001","title":"ALT-801 0.040 mg/kg/Dose"},{"description":"0.080 mg/kg/dose of ALT-801","id":"OG002","title":"ALT-801 0.080 mg/kg/Dose"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"24 months","title":"ALT-801 Induced Cell-mediated Immune Responses","type":"SECONDARY","unitOfMeasure":"IFNg spots per million PMBCs"}